NeuroPace (NASDAQ:NPCE) Coverage Initiated by Analysts at UBS Group

UBS Group assumed coverage on shares of NeuroPace (NASDAQ:NPCE) in a report released on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $17.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Wells Fargo & Company reduced their price target on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.33.

NeuroPace Stock Performance

NASDAQ NPCE opened at $14.02 on Tuesday. The firm’s fifty day moving average price is $11.22 and its two-hundred day moving average price is $8.56. NeuroPace has a 1 year low of $5.45 and a 1 year high of $18.15. The firm has a market capitalization of $418.47 million, a P/E ratio of -14.02 and a beta of 2.02. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. During the same period in the previous year, the company posted ($0.28) EPS. As a group, research analysts anticipate that NeuroPace will post -1 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NPCE. KCK LTD. bought a new position in NeuroPace in the 4th quarter valued at approximately $58,981,000. JPMorgan Chase & Co. raised its stake in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after acquiring an additional 6,181 shares during the last quarter. Barclays PLC raised its stake in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after acquiring an additional 16,007 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock worth $2,211,000 after purchasing an additional 25,330 shares during the period. Finally, State Street Corp grew its stake in shares of NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after purchasing an additional 12,912 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.